p53 protein accumulation as a prognostic marker of preoperative radiotherapy and/or chemotherapy in advanced squamous cell esophageal carcinoma preliminary report

Diseases of the Esophagus

Volumn 12, Issue 2, 1999, Pages 128-131

  Nasierowska Guttmejer, A ^a   Szawlowski A ^a   Jastrzebska, M ^a   Jeziorski, K ^a   Radziszewski, J ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COBALT 60; FLUOROURACIL; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CORRELATION FUNCTION; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR CLASSIFICATION; TUMOR REGRESSION; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032813837     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.1999.00030.x     Document Type: Article

References (19)

1. Zatoński W, Tyczyński J. Nowotwory złośliwe w Polsce w 1995 roku. Warszawa: Centrum Onkoloii-Instytut im M. Skłodowskiej-Curie, 1997.
2. Kerr F K, Winterford C M, Harmon B V. Apoptosis. Cancer 1994; 73: 2013-2026.
3. Locker D. Tumor suppressor genes and practice of surgical pathology. Hum Pathol 1995; 26: 359-361.
4. Sidransky D. Molecular markers in cancer: can we make better predictions? Int J Cancer 1995; 64: 1-2.
5. McLean M, Brierley J, Casson A G. Oesophageal cancer: hope for the future? Clin Oncol 1997; 9: 1-3.
6. Hardwick R H, Barham C P, Ozua P et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma: no correlation with prognosis. Eur J Surg Oncol 1997; 23: 30-35.
7. Chaves P, Pereira A D, Pinto A et al. p53 protein immunoexpression in esophageal squamous cell carcinoma and adjacent mucosa. J Surg Oncol 1997; 65: 3-9.
8. Coggi G, Bosari S, Roncalli M et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer 1997; 79: 425-432.
9. Igekuchi M, Saito H, Katano K et al. Radiochemosensitivity and expression of p53 in patients with esophageal cancer treated by absolute noncurative resection. Anticancer Res 1998; 18: 493-497.
10. Manges G M, Seitz J F, Giovannini M F et al. Prognostic value of p53 protein expression in squamous cell carcinoma of the esophagus. Cancer Detect Prev 1996; 20 (1): 63-67.
11. Forastiere A A, Oringer M B, Perez-Tamayo C et al. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 1990; 8: 119-127.
12. Darnton S J, Allen S M, Edwards C W, Matthews H R Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. J Clin Pathol 1993; 46: 51-55.
13. Mandard A M, Dalibard F, Mandard J C et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 1994; 73: 2680-2686.
14. Nasierowska-Guttmejer A, Szawłowski A, Falkowski S et al. Histopathological evaluation of response to pre-operative concurrent chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus. Dis Esophagus 1995; 8: 136-141.
15. Ellis P A, Smith I E, McCarthy K et al. Pre-operative chemotherapy induces apoptosis in early breast cancer. Lancet 1997; 349: 849.
16. Levine E L, Davidson S E, Roberts S A et al. Apoptosis as predictor of response to radiotherapy in cervical carcinoma. Lancet 1994; 344: 472.
17. Scott N, Hale A, Deakin M et al. A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. Eur J Surg Oncol 1998; 24: 169-173.
18. Casson A G, Kerkvliet N, O'Malley F et al. Prognostic value of p53 protein in esophageal adenocarcinoma. J Surg Oncol 1995; 60: 5-11.
19. Nabeya Y, Loganzo F, Maslak P et al. The mutation status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995; 64: 37-46.